HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elisabeth Pittermann Selected Research

Imatinib Mesylate (Gleevec)

6/2012Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Elisabeth Pittermann Research Topics

Disease

1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2012
1Hemorrhage
02/2012
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
02/2012
1Neoplasms (Cancer)
06/2006

Drug/Important Bio-Agent (IBA)

1Imatinib Mesylate (Gleevec)FDA Link
06/2012
1nilotinibFDA Link
06/2012
1Tyrosine Kinase InhibitorsIBA
06/2012
1Inosine Triphosphate (ITP)IBA
02/2012

Therapy/Procedure

1Therapeutics
06/2012
1Hematopoietic Stem Cell Mobilization
06/2006